ALA presents at Cell and Gene Therapy World Asia Conference
Arovella is pleased to announce it will present at the 8th Cell and Gene Therapy World Asia Conference in Singapore. Arovella’s CEO and MD, Dr Michael Baker, will present data describing the key benefits of Arovella’s proprietary iNKT cell therapy platform as truly “off-the-shelf” with the potential for improved efficacy across a range of oncology indications.
Highlights from the presentation include:
The “off-the-shelf” capabilities of Arovella’s CAR-iNKT platform
Potential benefits of CAR-iNKT cells over CAR-T in treating cancers
The enhanced tumour killing of CAR19-iNKT cells (ALA-101) relative to CAR-T cells
The significant survival benefit conferred by ALA-101 in animal models
Key advantages of Arovella’s proprietary manufacturing process
An update on the planned phase 1 clinical trial for ALA-101
The possibility of Arovella’s proprietary iNKT cell platform with novel CARs to target solid tumours
The potential benefit of Arovella’s cytokine ‘armouring’ technology, IL-12-TM